GB935672A - Sustained release tablet - Google Patents
Sustained release tabletInfo
- Publication number
- GB935672A GB935672A GB25563/61A GB2556361A GB935672A GB 935672 A GB935672 A GB 935672A GB 25563/61 A GB25563/61 A GB 25563/61A GB 2556361 A GB2556361 A GB 2556361A GB 935672 A GB935672 A GB 935672A
- Authority
- GB
- United Kingdom
- Prior art keywords
- hydrochloride
- optionally
- medicaments
- sustained release
- release tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000007939 sustained release tablet Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 abstract 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 abstract 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 abstract 1
- WNPNNLQNNJQYFA-QRPNPIFTSA-N 4-[(1r)-2-amino-1-hydroxyethyl]benzene-1,2-diol;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.NC[C@H](O)C1=CC=C(O)C(O)=C1 WNPNNLQNNJQYFA-QRPNPIFTSA-N 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 229930003347 Atropine Natural products 0.000 abstract 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 abstract 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 abstract 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- RCGYDFVCAAKKNG-UHFFFAOYSA-N Thenyldiamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC=1C=CSC=1 RCGYDFVCAAKKNG-UHFFFAOYSA-N 0.000 abstract 1
- HRYJPHOTGFERGT-UHFFFAOYSA-N Thonzylamine hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CC=N1 HRYJPHOTGFERGT-UHFFFAOYSA-N 0.000 abstract 1
- 229920002494 Zein Polymers 0.000 abstract 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 230000002921 anti-spasmodic effect Effects 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 229940124575 antispasmodic agent Drugs 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002810 chlormezanone Drugs 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229960003210 hyoscyamine Drugs 0.000 abstract 1
- 229930005342 hyoscyamine Natural products 0.000 abstract 1
- 239000003326 hypnotic agent Substances 0.000 abstract 1
- 239000003701 inert diluent Substances 0.000 abstract 1
- 229940018448 isoproterenol hydrochloride Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 229940051129 meperidine hydrochloride Drugs 0.000 abstract 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004815 meprobamate Drugs 0.000 abstract 1
- 229960001703 methylphenobarbital Drugs 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 abstract 1
- 229960003293 penthienate Drugs 0.000 abstract 1
- NEMLPWNINZELKP-UHFFFAOYSA-N penthienate Chemical compound C=1C=CSC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCC1 NEMLPWNINZELKP-UHFFFAOYSA-N 0.000 abstract 1
- 229960002695 phenobarbital Drugs 0.000 abstract 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 abstract 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 abstract 1
- 229960000581 salicylamide Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 229960004129 sorbitan tristearate Drugs 0.000 abstract 1
- 235000011078 sorbitan tristearate Nutrition 0.000 abstract 1
- 239000001589 sorbitan tristearate Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- BJVVMKUXKQHWJK-UHFFFAOYSA-N talbutal Chemical compound CCC(C)C1(CC=C)C(=O)NC(=O)NC1=O BJVVMKUXKQHWJK-UHFFFAOYSA-N 0.000 abstract 1
- 229960004000 talbutal Drugs 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
- 229960004636 thonzylamine hydrochloride Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 150000005691 triesters Chemical class 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000005019 zein Substances 0.000 abstract 1
- 229940093612 zein Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical sustained release tablet is composed of a solid medicament uniformly distributed in a matrix composed essentially of zein (preferably 45-75% by weight) and a solid hexitan tri-ester of a higher aliphatic acid, e.g. sorbitan tristearate (preferably 25-55%). Optionally there may also be present about 1-3% of a tableting lubricant and up to 33% (of the matrix) of an inert diluent. Specified medicaments are antispasmodics, e.g. penthienate bromide, atropine and hyoscyamine; barbiturates, e.g. phenobarbital, mephobarbital and talbutal; tranquilizers, e.g. meprobamate; antihistamines, e.g. dethylandiamine hydrochloride and thonzylamine hydrochloride; antibiotics, e.g. tetracycline and procaine penicillin; vasodilators, e.g. pentaerythritol tetranitrate; vasopressors, e.g. levarterenol bitartrate, phenylephrine hydrochloride and isoproterenol hydrochloride; muscle relaxants, e.g. chlormethazanone; analgesics, e.g. meperidine hydrochloride, acetyl salicylic acid and salicylamide; vitamins, hormones and anti-infective, sedative and hypnotic agents. The tablets may optionally be coated and the coatings may contain the same or other medicaments to the core.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4374060A | 1960-07-19 | 1960-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB935672A true GB935672A (en) | 1963-09-04 |
Family
ID=21928651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB25563/61A Expired GB935672A (en) | 1960-07-19 | 1961-07-14 | Sustained release tablet |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE606331A (en) |
| FR (1) | FR1314M (en) |
| GB (1) | GB935672A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0158277A3 (en) * | 1984-04-11 | 1987-04-29 | Hoechst Aktiengesellschaft | Implantable controlled-release preparations of regulatory peptides, and process for their preparation |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| WO2002043706A3 (en) * | 2000-12-01 | 2003-03-27 | Labopharm Inc | Prolamin-based sustained-release compositions and delayed-onset compositions |
| CN101669899B (en) * | 2009-09-29 | 2011-02-02 | 河北科技大学 | Sustained-release implant taking maize protein as main framework material or matrix and use thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4137300A (en) * | 1976-08-20 | 1979-01-30 | Ciba-Geigy Corporation | Sustained action dosage forms |
-
1961
- 1961-07-14 GB GB25563/61A patent/GB935672A/en not_active Expired
- 1961-07-18 FR FR868250A patent/FR1314M/en active Active
- 1961-07-19 BE BE606331A patent/BE606331A/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0158277A3 (en) * | 1984-04-11 | 1987-04-29 | Hoechst Aktiengesellschaft | Implantable controlled-release preparations of regulatory peptides, and process for their preparation |
| US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
| WO1993012772A1 (en) * | 1991-12-31 | 1993-07-08 | Abbott Laboratories | System for delivering an active substance for sustained release |
| WO2002043706A3 (en) * | 2000-12-01 | 2003-03-27 | Labopharm Inc | Prolamin-based sustained-release compositions and delayed-onset compositions |
| CN101669899B (en) * | 2009-09-29 | 2011-02-02 | 河北科技大学 | Sustained-release implant taking maize protein as main framework material or matrix and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FR1314M (en) | 1962-05-14 |
| BE606331A (en) | 1962-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE4956T1 (en) | PREPARATION CONTAINING NITROGLYCERIN AND POSSIBLY OTHER MEDICATIONS AND THEIR MANUFACTURE. | |
| ES267532A1 (en) | Pharmaceuticals with delayed release | |
| DE69630798D1 (en) | AEROSOL COMPOSITIONS | |
| CA936472A (en) | Formulation for sustained release of a biological agent | |
| ATE78157T1 (en) | SLOW-RELEASE PHARMACEUTICALS. | |
| ATE84032T1 (en) | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. | |
| ES370952A1 (en) | Rumen stable medicament and/or nutrient compositions | |
| GB935672A (en) | Sustained release tablet | |
| ES2062697T3 (en) | PROCEDURE FOR THE INCORPORATION IN PELLETS OF ACTIVE PRINCIPLES PROTECTED AGAINST DEGRADATION IN THE TUMMY OF RUMINANTS. | |
| NO891220D0 (en) | COMPOSITION CONTAINING SALICYLIC ACID FOR TREATING LEPIDOSE. | |
| ES2043943T3 (en) | PROCEDURE FOR THE PREPARATION OF COMPOUNDS WITH CENTRAL ANALGESIC ACTIVITY. | |
| JPS5242533A (en) | Two-pack adhesive composition | |
| ES8502111A1 (en) | Diniflumate of morpholinoethyl ester of niflumic acid, its preparation, and its use in analgesic and antiinflammatory pharmaceutical compositions. | |
| AU3106071A (en) | Novel thionothiolphosphoric acid ester amides, a process for their preparation and their use as nematocil insecticides and acaricides | |
| Forbes et al. | An evaluation of flurbiprofen, aspirin, and placebo in postoperative oral surgery pain | |
| GB1261989A (en) | 5-thiazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing the same | |
| AR217223A1 (en) | NEW ESTER ESTERS AND AMIDES OF O-TRIAZOLYLLIONOPHOSPHORIC AND O-TRIAZOLYLTIONOPHOSPHONIC ACIDS OF INSECTICIDE AND PHYTOACARICIDES PROPERTIES, INSECTICIDE AND ACARICIDE COMPOSITIONS FOR THE SAME PRODUCTS AND ACARICIDES | |
| GB1108299A (en) | Sustained release dosage forms and their preparation | |
| FR1974M (en) | Medicinal product based on a complex of vitamin b12 and tannin. | |
| FR1278737A (en) | Support for dispensing flat objects such as disks, toast, rusks and the like | |
| FR2280379A1 (en) | Indol-1-ylacetates - with analgesic but negligible antiinflammatory activity | |
| FR39M (en) | New drug usable as local anesthetic and spasmolytic, based on homomyrtenyloxy-2 diethylamino-1 ethane | |
| FR2469924A1 (en) | LONG-ACTING INJECTABLE PHARMACEUTICAL COMPOSITION CONTAINING SULFAMETHOXAZOLE AND TRIMETHOPRIME AS ACTIVE AGENTS AND PROCESS FOR PREPARING THE SAME | |
| ES351635A1 (en) | Kallikrein-Inactivator Derivatives | |
| USD181287S (en) | Lamp post |